Early diagnosis of acute renal injury in patients with acute decompensation of chronic heart failure

Nasonova, Svetlana N.; Жиров, И. В.; Ledyakhova, M V; Шарф, Т. В.; Bosykh, E G; Масенко, В П; Tereshchenko, S. N.

doi:10.26442/00403660.2019.04.000168

Cited by 6 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Numerous recent studies have confirmed that NGAL might be a predictive marker of acute kidney injury due to heart failure. The report by Nasonova proved that increased urine NGAL concentrations were prognostic markers of kidney function decreases in patients with acute decompensation of chronic heart failure [ 193 ]. The study of Dankova also proved elevated urine NGAL levels at admission to the hospital due to acute HF and predicted the following development of AKI [ 194 ].…”

Section: The Role Of Ngal In Cardiovascular Diseasesmentioning

confidence: 99%

The Review of Current Knowledge on Neutrophil Gelatinase-Associated Lipocalin (NGAL)

Romejko¹,

Markowska²,

Niemczyk³

2023

IJMS

View full text Add to dashboard Cite

Neutrophil gelatinase-associated lipocalin (NGAL) is a 25-kDa protein that is secreted mostly by immune cells such as neutrophils, macrophages, and dendritic cells. Its production is stimulated in response to inflammation. The concentrations of NGAL can be measured in plasma, urine, and biological fluids such as peritoneal effluent. NGAL is known mainly as a biomarker of acute kidney injury and is released after tubular damage and during renal regeneration processes. NGAL is also elevated in chronic kidney disease and dialysis patients. It may play a role as a predictor of the progression of renal function decreases with complications and mortality due to kidney failure. NGAL is also useful in the diagnostic processes of cardiovascular diseases. It is highly expressed in injured heart tissue and atherosclerostic plaque; its serum concentrations correlate with the severity of heart failure and coronary artery disease. NGAL increases inflammatory states and its levels rise in arterial hypertension, obesity, diabetes, and metabolic complications such as insulin resistance, and is also involved in carcinogenesis. In this review, we present the current knowledge on NGAL and its involvement in different pathologies, especially its role in renal and cardiovascular diseases.

show abstract

Section: The Role Of Ngal In Cardiovascular Diseasesmentioning

confidence: 99%

The Review of Current Knowledge on Neutrophil Gelatinase-Associated Lipocalin (NGAL)

Romejko¹,

Markowska²,

Niemczyk³

2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Таким образом, выявление маркеров, позволяющих спрогнозировать и определить поражение функции почек на начальном этапе, поможет оценить риски наступления неблагоприятного исхода среди больных ОДСН. Так, в исследовании 60 пациентов с ОДСН и сниженной фракцией выброса ОПП зарегистрировано у 48,3% больных, у которых в сыворотке крови определялись уровень липокалина, ассоциированный с NGAL, цистатина С, а также показатели молекулы повреждения почек-1 и ангиотензиногена в моче [8]. Риск развития ОПП у пациентов с ОДСН увеличивался при следующих концентрациях биомаркеров: NGAL >157,35 нг/мл -в 13,1 раза (95% ДИ 1,365-126,431), молекул повреждения почек-1 >1,81 нг/мл -в 20,6 раза (95% ДИ 1,802-235,524), ангиотензиногена >14,31 нг/млв 32,8 раза (95% ДИ 2,752-390,110).…”

Section: биомаркеры в диагностике острых декомпенсации сердечной недостаточности и почечного поврежденияunclassified

“…Изменения креатинина на ранних этапах (48-72 ч с момента госпитализации) у пациентов с почечной недостаточностью (24,7% при измерении креатинина сыворотки и 42,8% при расчете скорости клубочковой фильтрации) имели более высокую распространенность колебаний, а случаи летального исхода составили 16,2% [5]. ОПП -частое осложнение ОДСН, возникающее в 20-70% случаев и повышающее риск смертности от ССЗ до 86% [6][7][8]. На сегодняшний день распространены данные о том, что у большинства пациентов с ХСН и ОДСН заболевания сердца и почек часто связаны: выявленная связь закреплена термином «кардиоренальный синдром».…”

Section: Introductionunclassified

Biomarkers and the prediction of adverse outcomes in patients with acute decompensated heart failure and kidney injury

Глизер

Штегман

Петрова

2021

Kompleks. probl. serdečno-sosud. zabol.

View full text Add to dashboard Cite

Abstract. Chronic heart failure is one of the main contributors to the Global Burden of Cardiovascular Diseases. Despite advances in modern treatment, acute decompensated heart failure (ADHF) incidence is high. Moreover, patients admitted for ADHF encounter renal impairment, which is another predictor of adverse outcome. There are number of biomarkers that allow clinicians to assess the prognosis of the disease in the early stages. The article presents an overview of contemporary biomarkers (utilizing multimarker approach), and identifies the most significant biological markers for evaluating ADHF and worsening renal function.

show abstract

Urine N-terminal pro-B-type natriuretic peptide and plasma proenkephalin are promising biomarkers for early diagnosis of cardiorenal syndrome type 1 in acute decompensated heart failure: a prospective, double-center, observational study in real-world

Zhao

et al. 2022

Renal Failure

View full text Add to dashboard Cite

Background Patients with acute decompensated heart failure (ADHF) show cardiorenal syndrome type 1 (CRS-1) are more likely to have a poor outcome. However, the current criteria often lead to delayed CRS-1 diagnosis. Therefore, we evaluated the predictive value of plasma proenkephalin (pPENK) and urine NT-proBNP (uNT-proBNP) for early diagnosis of CRS-1 and vulnerable-phase prognosis in ADHF patients. Methods The plasma NT-proBNP (pNT-proBNP), pPENK, and uNT-proBNP were measured in 121 ADHF patients on admission. The plasma neutrophil gelatinase-associated lipocalin (pNGAL) was chosen as the reference. Logistic regression was used to determine the predictors of CRS-1. The area under the receiver operating curves (ROCs) was calculated to assess the early diagnostic value of pNGAL, pPENK, and uNT-proBNP/uCr for CRS-1. To evaluate the prognostic risk of factors for the 90-d outcomes of all ADHF patients, the Cox regression was performed and the cumulative risk curve was plotted. Results We found that pPENK [OR 1.093 (95% CI 1.022–1.169), p = 0.010; AUROC = 0.899 (95% CI 0.831–0.946)] and uNT-proBNP/uCr ratio [OR 1.015 (95% CI 1.003–1.028), p = 0.012; AUROC = 0.934 (95% CI 0.874–0.971)] could independently predict the occurrence of CRS-1 in hospitalized patients with ADHF. The pPENK [HR 1.014 (95% CI 1.000–1.042), p = 0.044] and uNT-proBNP/uCr ration [HR 0.998 (95% CI 0.997–1.000), p = 0.045] were also independent predictors of the risk of HF readmission or all-cause death 90 d after discharge in ADHF patients. Conclusions The newly found pPENK and noninvasive test of uNT-proBNP/uCr ratio (pg/nmol) on admission may be two promising novel predictive biomarkers for early diagnosis of CRS-1 occurrence and vulnerable-phase outcomes in ADHF patients.

show abstract

Early diagnosis of acute renal injury in patients with acute decompensation of chronic heart failure

Cited by 6 publications

References 27 publications

The Review of Current Knowledge on Neutrophil Gelatinase-Associated Lipocalin (NGAL)

The Review of Current Knowledge on Neutrophil Gelatinase-Associated Lipocalin (NGAL)

Biomarkers and the prediction of adverse outcomes in patients with acute decompensated heart failure and kidney injury

Urine N-terminal pro-B-type natriuretic peptide and plasma proenkephalin are promising biomarkers for early diagnosis of cardiorenal syndrome type 1 in acute decompensated heart failure: a prospective, double-center, observational study in real-world

Contact Info

Product

Resources

About